What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment-Reference-Cited by-同舟云学术

What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment

Published:2014 Issue:1 Volume:13 Page:8
ISSN:1744-859X
Container-title:Annals of General Psychiatry
language:en
Short-container-title:Ann Gen Psychiatry

Author:

Ball Susan,Classi Peter,Dennehy Ellen B

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health

Reference18 articles.

1. The Epidemiology of Major Depressive Disorder

2. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010

3. The Economic Burden of Depression in the United States

4. A Review of Current Guidelines for Depression Treatment

5. Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prescribing behavior of antidepressants for depressive disorders: A systematic review;Frontiers in Psychiatry;2022-09-09

2. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries;European Archives of Psychiatry and Clinical Neuroscience;2022-01-06

3. Switches and early discontinuations of antidepressant medication in young adults with depression;Journal of Affective Disorders;2021-12

4. The Role of Chemokines in the Pathophysiology of Major Depressive Disorder;International Journal of Molecular Sciences;2019-05-09

5. Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study;Psychological Medicine;2018-07-02